Core Viewpoint - The announcement highlights that the company's subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., has developed an inhalation solution of human interferon α 1b, which has been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration's Drug Review Center [1] Group 1: Product Development - The inhalation solution is a significant breakthrough in the antiviral field, specifically designed for children [1] - The product is administered via nebulization, allowing the active ingredient to reach the site of infection more quickly compared to injection [1] - The solution is indicated for pediatric respiratory syncytial virus lower respiratory tract infections, including pneumonia and bronchiolitis [1] Group 2: Advantages of the Product - The inhalation method eliminates the pain associated with injections, leading to higher acceptance and safety for pediatric patients [1] - The broad-spectrum antiviral, antitumor, and immune-regulating properties of interferon make it a key component of the body's natural immunity [1]

Core Viewpoint - The announcement highlights that the inhalation solution of human interferon α 1b, developed by the company's wholly-owned subsidiary, has been included in the list of breakthrough therapies by the National Medical Products Administration [1] Group 1: Product Development - The human interferon α 1b inhalation solution is a significant breakthrough in the antiviral field for the company [1] - This medication is specifically designed for children and is administered via nebulization, allowing the active ingredient to reach the site of infection more quickly [1] - Compared to injectable forms, this inhalation solution offers higher acceptance and safety for pediatric patients, as they do not have to endure the pain of injections [1] Group 2: Indications and Applications - The indication for the human interferon α 1b inhalation solution is for pediatric respiratory syncytial virus (RSV) lower respiratory tract infections, including pneumonia and bronchiolitis [1]